We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksValiRx Share News (VAL)

Share Price Information for ValiRx (VAL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.35
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.10 (3.03%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 3.35
VAL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

London afternoon: Back to square one

Mon, 24th May 2010 13:42

Footsie has limped back into positive territory, helped by an about turn by the mining stocks.After spending the morning down in the dumps Rio Tinto is now the best performing mining stock as metal prices head northwards. Fellow mining stocks Xstrata and Anglo American join Rio on the rise but South African platinum miner Lonmin is still on the slide after its plans to get its Number One furnace back fully on line hit a snag that will add around 25-30 days to the commissioning process. The oil disaster in the Gulf of Mexico has cost BP about $760m (£525m) so far and the under-fire oil giant faces being "pushed out of the way" if its clean-up operation doesn't do better. So far 23,000 claims have been filed in relation to the MC252 oil well spill and 9,000 have already been paid. A week ago, it had cost the company about $625m.Peers Cairn Energy, Tullow Oil and Royal Dutch Shell are also among the worst performers.On the positive side, Prudential is wanted on reports that US firm AIG has drawn up plans to float its Asian arm again if the Pru's attempts to buy it collapse.British Airways has given up early gains. Cabin crew started their strike today despite last ditch attempts to get it averted.Travellers face massive disruption despite BA's attempt to fly as many planes as possible, although it had looked like industrial action could be avoided following a last-minute overture from the Unite union.Invensys grew full-year profit, though not by as much as analysts would have liked, but the firm still remains positive about the outlook based on its large order book and view of economic conditions. Profits fell by 25% at bid target Chloride last year, as recession hit its markets in Europe and the US. The power supplies group saw profits fall to £29.9m from £39.8m in the year to March, after a £5.9m one-of charge. Adjusted operating profits fell 4% to £44.7m. Sales rose by 3% to £336m.Pork products supplier Cranswick brought home the bacon last year, delivering a 26% surge in annual pre-tax profit. Revenues were up 22% to £740m. Net debt reduced by £11.9m to £54.7m. The company said it is encouraged by the positive start made in the current financial year. AG Barr, the Scottish soft drinks maker best known for its iconic Irn Bru concoction, said sales have continued frothing over in the new financial year.Recession has kept Albemarle & Bond's pawnbroker business performing strongly and it expects results for the 12 months to June 2010 to meet market expectations.Oil companies Europa and Aurelian are wanted after good progress on the Voitinel-1 well in the Brodina Block in Romania, in which they both have sizeable stakes.ValiRx, the biotech firm, has added Biovei's over the counter Chlamydia self-testing kit to its range of health screening products. Biomaterials and medical devices group Aortech has announced a non-exclusive technology licence and material supply agreement with a multi-billion dollar NYSE listed company to use the group's proprietary biostable co-polymer Elast-Eo as an integral part of a drug delivery platform for urological catheters.
More News
10 Feb 2020 16:00

UK Shareholder Meetings Calendar - Next 7 Days

UK Shareholder Meetings Calendar - Next 7 Days

Read more
14 Jan 2020 14:50

ValiRx signs letter of intent in a bid to fund VAL401

(Sharecast News) - Clinical-stage biotechnology company ValiRx updated the market on its subsidiary joint venture, ValiSeek, and its cancer therapeutic, VAL401 on Tuesday.

Read more
14 Jan 2020 11:08

ValiRx Joint Venture Partner Enters Agreement For VAL401 Funding

ValiRx Joint Venture Partner Enters Agreement For VAL401 Funding

Read more
6 Jan 2020 09:59

ValiRx Raises GBP200,000 To Progress Product Development

ValiRx Raises GBP200,000 To Progress Product Development

Read more
16 Dec 2019 10:17

ValiRx Reveals "Clear Impact" Of VAL201 On Prostate Cancer Patients

ValiRx Reveals "Clear Impact" Of VAL201 On Prostate Cancer Patients

Read more
28 Nov 2019 16:13

ValiRx granted US patent for 'VAL201' compound

(Sharecast News) - Clinical stage biotechnology company ValiRx announced on Thursday that the US Patent and Trademark Office has granted patent number 10,400,008, titled 'Modulators Of The SRC-Kinase Activity For Preventing Or Treating Metastatic Cancer', to its lead therapeutic compound 'VAL201'.

Read more
28 Nov 2019 15:57

ValiRx Granted "Key" US Patent Protection For VAL201 Cancer Treatment

ValiRx Granted "Key" US Patent Protection For VAL201 Cancer Treatment

Read more
14 Oct 2019 13:44

ValiRx Raises GBP350,000 Through Placing To Progress Clinical Trials

ValiRx Raises GBP350,000 Through Placing To Progress Clinical Trials

Read more
26 Sep 2019 11:43

ValiRx Reports Narrowed Loss In First Half As Expenses Reduce

ValiRx Reports Narrowed Loss In First Half As Expenses Reduce

Read more
24 Sep 2019 12:40

ValiRx Receives GBP423,000 Research & Development Credit From UK HMRC

ValiRx Receives GBP423,000 Research & Development Credit From UK HMRC

Read more
10 Sep 2019 13:45

ValiRx Prostate Cancer Drug VAL201 Still Meeting Endpoints

(Alliance News) - ValiRx PLC on Tuesday said its VAL201 lead compound is still meeting all of its published endpoints and is behaving as expected in prostate cancer.VAL201 has been as a and

Read more
1 Aug 2019 12:01

ValiRx Granted European Patent Allowance For VAL301 Compound

(Alliance News) - Clinical stage biotechnology firm ValiRx PLC said Thursday it has been granted a patent notice of allowance for its pre-clinical therapeutic compound, VAL301, from the European a

Read more
23 Jul 2019 16:25

Monecor Takes Nearly 6% Holding In Biotechnology Firm ValiRx

(Alliance News) - ValiRx PLC on Tuesday said Monecor London Ltd now holds 5.7% interest in the biotechnology company.Prior to this transaction on Monday, Monecor's holding totalled were

Read more
26 Jun 2019 14:30

US Grands Patent Claim For valiRx's VAL201 In Metastatic Cancer

(Alliance News) - ValiRx PLC on Wednesday said the US has allowed a patent claim for the use of VAL201 in metastatic cancer.Shares in ValiRx were down 7.1% at 0.21 pence in afternoon trade

Read more
26 Jun 2019 10:53

ValiRx gets US patent protection for use of VAL201 peptide

(Sharecast News) - Clinical stage biotechnology company ValiRx announced on Wednesday that the US Patent and Trademark Office (USPTO) has allowed patent claims directed towards a method of preventing the worsening of symptoms of metastatic cancer, reducing the progression of metastatic cancer, or treating metastatic cancer - including prostate cancer - by administration of the 'VAL201' peptide.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.